Alios BioPharma, Inc.

Alios BioPharma, Inc.

Alios BioPharma, Inc.

Overview
Date Founded

2008

Headquarters

260 East Grand Avenue,2nd floor,San Francisco, CA 94080

Type of Company

Private

Employees (Worldwide)

51 - 100

Industries

Pharmaceuticals
Biotechnology

Company Description

Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA.

Contact Data
Trying to get in touch with decision makers at Alios BioPharma, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Vice President-Drug Discovery

Head-Media Relations

Senior Director-Operations

Director of Information Technology

Director

Marketing Director

Principal

Associate Director

Associate Director

Principal Scientist

Board of Directors

Research Scientist at Max Planck Society

Managing Director at Novartis Venture Fund

Director & Managing Partner at Action Potential Venture Capital

Partner at TPG Growth LLC

Paths to Alios BioPharma, Inc.
Potential Connections via
Relationship Science
You
Alios BioPharma, Inc.
Recent Transactions
Details Hidden

Johnson & Johnson purchases Alios BioPharma, Inc. from GSK Equity Investments Ltd, Novartis Venture Fund, Roche Ventures, Novo Ventures 1 A/S

Details Hidden

Alios BioPharma, Inc. raised money in a private placement transaction

Details Hidden

Alios BioPharma, Inc. raised money in a private placement transaction

Transaction Advisors
Investment Advisor

Advised onJohnson & Johnson purchases Alios BioPharma, Inc. from GSK Equity Investments Ltd, Novartis Venture Fund, Roche Ventures, Novo Ventures 1 A/S

Legal Advisor

Advised onJohnson & Johnson purchases Alios BioPharma, Inc. from GSK Equity Investments Ltd, Novartis Venture Fund, Roche Ventures, Novo Ventures 1 A/S

Legal Advisor

Advised onJohnson & Johnson purchases Alios BioPharma, Inc. from GSK Equity Investments Ltd, Novartis Venture Fund, Roche Ventures, Novo Ventures 1 A/S

Legal Advisor

Advised onJohnson & Johnson purchases Alios BioPharma, Inc. from GSK Equity Investments Ltd, Novartis Venture Fund, Roche Ventures, Novo Ventures 1 A/S

Legal Advisor

Advised onJohnson & Johnson purchases Alios BioPharma, Inc. from GSK Equity Investments Ltd, Novartis Venture Fund, Roche Ventures, Novo Ventures 1 A/S

Advisors & Consultants
Legal Advisor

Partner at Latham & Watkins LLP

Non-Profit Donations & Grants
$50K +
2017
Investors
Details Hidden

Chief Executive Officer & Director at Aligos Therapeutics, Inc.

Details Hidden

SR One invests in companies located in the US and the UK. The firm targets companies operating in the fields of biotechnology. It provides financing for early stage capital requirements.

Details Hidden

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation’s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alios BioPharma, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alios BioPharma, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Alios BioPharma, Inc..